Retrospective Study Looks at GLP1 Drugs and Alcohol Use Disorder
Maya Lindqvist · Lead Science Writer
November 15, 2026 · 1 min read
A retrospective cohort study set for publication in the European Journal of Internal Medicine examines adults with overweight or obesity who also have a diagnosed alcohol use disorder, comparing outcomes for those prescribed a GLP1 receptor agonist such as semaglutide against those who were not, according to the study listing on PubMed.
This design matters for how readers should weigh any findings. A retrospective cohort study pulls existing medical records rather than randomizing participants to a treatment, so it can flag associations worth testing further, but it cannot establish that a GLP1 drug caused any change in drinking behavior or related outcomes. Factors like why a clinician chose to prescribe one patient a GLP1 agonist and not another can shape results in ways statistics only partly correct for.
Interest in this question has grown as patients and clinicians have reported anecdotal drops in alcohol cravings alongside GLP1 therapy for weight management, prompting researchers to look at insurance and health system data for signals. Until prospective, randomized trials are run specifically in populations with alcohol use disorder, this kind of retrospective analysis is best read as hypothesis generating rather than practice changing. No GLP1 receptor agonist is approved specifically to treat alcohol use disorder.
This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.
Ready to explore peptides?
Browse every compound profile or work out your dose with the reconstitution calculator.


